<DOC>
	<DOCNO>NCT02202200</DOCNO>
	<brief_summary>An open label multicentre , phase I-II study tumour molecular pharmacodynamics ( MPD ) evaluation pharmacokinetics PD-0332991 add vemurafenib patient suffer metastatic melanoma BR . The main objective establish Maximum Tolerated Dose ( MTD ) PD-0332991 add standard vemurafenib therapy ( 960 mg BID ) . The estimated MTD define dose PD-0332991 combine vemurafenib associate prespecified proportion patient experience Dose-Limiting Toxicity ( DLT ) , ie , 1/3 .</brief_summary>
	<brief_title>Phase I-II Study With Tumor Molecular Pharmacodynamic ( MPD ) Evaluation Pharmacokinetics PD-0332991 Patients Suffering Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Age &gt; 18 year Stage IV unresectable stage III melanoma Presence BRAF V600E/K mutation CDNKN2A loss expression Rb use immunohistochemistry recent metastatic sample ( &lt; 6 month ) A previous exposure BRAF inhibitor combination BRAF MEK inhibitor therapy allow unless stop 3 month study enrolment ( This define two strata trial ) No previous therapy MEK inhibitor unless associate BRAF inhibitor No previous therapy AKT/PI3K pathway inhibitor Patients tumour available repeated biopsy pharmacodynamics evaluation Life expectancy &gt; 3 month ECOG performance status &lt; 2 Signed inform consent Patient health insurance coverage No patient guardianship curator Inadequate hepatic function define serum bilirubin &gt; 25 μmol/l , transaminases &gt; 3.0 time upper limit normal ( ULN ) 5ULN case liver metastasis ; Inadequate bone marrow function define absolute neutrophil count &lt; 1500/mcl , platelet &lt; 150000/mcl haemoglobin &lt; 8g/dL Inadequate renal function serum creatinine &gt; 2.0mg/dl ) /or creatinine clearance &lt; 60 ml/min Untreated brain metastasis : Patients brain metastasis eligible complete treatment 1 month prior start study medication , discontinue corticosteroid treatment metastasis least 5 day , neurologically asymptomatic Myocardial infarct unstable angina within past 6 month Concomitant take drug know strong inhibitor inducer CYP314 HIV positive . Chemotherapy , immunotherapy within 4 week Drugs interfere PD0332991 vemurafenib metabolism Malabsorption syndrome condition would interfere enteral absorption Congenital long QT syndrome screen QTc &gt; 470 msec Need chronic corticosteroid therapy ≥10 mg prednisone per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>BRAF mutate</keyword>
</DOC>